EGFR and lung carcinoma: Gefitinib (IressaTM, ZD-1839) was the first EGFR tyrosine kinase inhibitor (TKI) that was approved by the FDA, in 2003, to be used as the first line of treatment for lung cancer with mutated EGFR (Figure 7) [110,111].